GSK Arexvy Protects From RSV Over Three Full Seasons
EXACT Therapeutics Partners With Agenus in Cancer Research
GSK's Respiratory Syncytial Virus Vaccine Given Together With Shingles Shot Shows Non-Inferior Immune Response In Older Adults
GSK Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX
Agenus Sued by Shareholder for Misleading Investors Over Colorectal Cancer Immuno-Therapy Trial Results
Botensilimab/Balstilimab Clinical Activity in Refractory Sarcomas to Be Presented in Oral Session at ESMO 2024
Agenus to Participate in September Investor Conferences
Agenus Analyst Ratings
B. Riley Adjusts Price Target on Agenus to $18 From $42, Maintains Buy Rating
Express News | Agenus Inc : B. Riley Cuts Target Price to $18 From $42
B.Riley Financial Maintains Agenus(AGEN.US) With Buy Rating, Cuts Target Price to $18
B.Riley Financial analyst Mayank Mamtani maintains $Agenus(AGEN.US)$ with a buy rating, and adjusts the target price from $42 to $18.According to TipRanks data, the analyst has a success rate of 25.3%
Agenus: Strong Clinical Potential Amidst Regulatory Challenges and Revised Market Entry Forecast
Agenus Appoints New Director and Plans Equity Offering
Agenus | 10-Q: Q2 2024 Earnings Report
Agenus Hold Rating: Balancing Phase 2 Progress With Regulatory Challenges and Uncertainty
Agenus GAAP EPS of -$2.52 Misses by $1.19, Revenue of $23.51M Misses by $39.97M
Express News | Agenus Inc: Qtrly Shr Loss $2.52
Earnings Flash (AGEN) AGENUS Reports Q2 Revenue $23.5M, Vs. Street Est of $63.5M
Express News | Agenus Reports Second Quarter 2024 Operational and Financial Results
Agenus Announces Appointment of Tom Harrison to Board of Directors